Otsuka Pharmaceutical Constructs First Overseas Factory In Suzhou
This article was originally published in PharmAsia News
Japan's Otsuka Pharmaceutical Factory, a subsidiary of the Otsuka Group, has laid the foundation for its first overseas investment - Suzhou Otsuka Pharmaceutical - in Suzhou Industrial Park. Otsuka Pharmaceutical Factory is to inject a total of $78 million into Suzhou Otsuka's construction. The facility will develop and produce injection-based medical products to be launched in both domestic and overseas markets. Since establishing China Otsuka Pharmaceutical in Tianjin in 1981, Otsuka Group has developed a network of 20 firms in the country. (Click here for more - Chinese Language)
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.